FindTrial
Sign In

N/A - AMINO BESTDOSE

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2019-001837-15-FR
Enrollment
260
Registered
2019-05-03
Start date
2019-10-08
Completion date
Unknown
Last updated
2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 20.0 Level: PT Classification code 10040070 Term: Septic shock System Organ Class: 10021881 - Infections and infestations

Interventions

Trade Name: AMIKACINE MYLAN 500 mg, poudre pour solution injectable Product Name: AMIKACINE Pharmaceutical Form: Powder for solution for injection/infusion

Sponsors

CHU de NIMES
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

France

Contacts

Public ContactDirection de la Recherche

CHU DE NIMES

drc@chu-nimes.fr33466 68 68 36

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026